id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2000-D-0187-0052,FDA,FDA-2000-D-0187,Reference 5 - Malaria _ CDC Yellow Book 2024,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:55:21Z,,0,0,09000064868c15dc
FDA-2000-D-0187-0057,FDA,FDA-2000-D-0187,Reference 10 - Mungai M,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:56:15Z,,0,0,09000064868c15e1
FDA-2000-D-0187-0053,FDA,FDA-2000-D-0187,Reference 6 - Local Transmission of I Plasmodium vivax I Malaria --- Palm Beach County Florida 2003,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:55:34Z,,0,0,09000064868c15dd
FDA-2000-D-0187-0065,FDA,FDA-2000-D-0187,Reference 18 - Khan J,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:57:36Z,,0,0,09000064868c15f5
FDA-2000-D-0187-0072,FDA,FDA-2000-D-0187,Recommendations To Reduce the Risk of Transfusion-Transmitted Malaria; Draft Guidance for Industry,Other,Guidance,2025-01-16T05:00:00Z,2025,1,2025-01-16T05:00:00Z,2025-03-18T03:59:59Z,2025-03-22T01:00:44Z,,1,0,09000064868c694a
FDA-2000-D-0187-0050,FDA,FDA-2000-D-0187,Reference 3 - Doolan D,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:55:01Z,,0,0,09000064868c156b
FDA-2000-D-0187-0062,FDA,FDA-2000-D-0187,Reference 15 - Stubbs L,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:57:09Z,,0,0,09000064868c15f2
FDA-2000-D-0187-0064,FDA,FDA-2000-D-0187,Reference 17 - Dike A,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:57:27Z,,0,0,09000064868c15f4
FDA-2000-D-0187-0056,FDA,FDA-2000-D-0187,Reference 9 - Muneer A,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:56:04Z,,0,0,09000064868c15e0
FDA-2000-D-0187-0049,FDA,FDA-2000-D-0187,Reference 2 - World Malaria Report 2022,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:54:49Z,,0,0,09000064868c156a
FDA-2000-D-0187-0070,FDA,FDA-2000-D-0187,Reference 23 Malaria Surveillance United States 2016 MMWR,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:58:21Z,,0,0,09000064868c161c
FDA-2000-D-0187-0051,FDA,FDA-2000-D-0187,Reference 4 - Mace K,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:55:11Z,,0,0,09000064868c15db
FDA-2000-D-0187-0059,FDA,FDA-2000-D-0187,Reference 12 - Uneke C,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:56:37Z,,0,0,09000064868c15e3
FDA-2000-D-0187-0063,FDA,FDA-2000-D-0187,Reference 16 - Neiderhauer C,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:57:18Z,,0,0,09000064868c15f3
FDA-2000-D-0187-0061,FDA,FDA-2000-D-0187,Reference 14 - Anand A,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:56:57Z,,0,0,09000064868c15f1
FDA-2000-D-0187-0054,FDA,FDA-2000-D-0187,Reference 7 - Blackburn D,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:55:44Z,,0,0,09000064868c15de
FDA-2000-D-0187-0066,FDA,FDA-2000-D-0187,Reference 19 - Israelyan N,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:57:46Z,,0,0,09000064868c15f6
FDA-2000-D-0187-0048,FDA,FDA-2000-D-0187,Reference 1 -Guidance for Industry.  Recommendations to Reduce the Risk of Transfusion-Transmitted  Malaria,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:54:30Z,,0,0,09000064868c1569
FDA-2000-D-0187-0055,FDA,FDA-2000-D-0187,Reference 8 - Duwell M,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:55:54Z,,0,0,09000064868c15df
FDA-2000-D-0187-0071,FDA,FDA-2000-D-0187,Reference-24 Malaria Surveillance United States 2017 MMWR,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:58:29Z,,0,0,09000064868c161d
FDA-2000-D-0187-0069,FDA,FDA-2000-D-0187,Reference 22-MalariaRBDMAnalysis_FINAL_2024-05-28,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:58:13Z,,0,0,09000064868c15f9
FDA-2000-D-0187-0060,FDA,FDA-2000-D-0187,Reference 13 - Katz L,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:56:49Z,,0,0,09000064868c15e4
FDA-2000-D-0187-0068,FDA,FDA-2000-D-0187,Reference 21- Blood Products Advisory Committee May 9..,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:58:04Z,,0,0,09000064868c15f8
FDA-2000-D-0187-0067,FDA,FDA-2000-D-0187,Reference 20 - cobas Malaria _ FDA,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:57:55Z,,0,0,09000064868c15f7
FDA-2000-D-0187-0047,FDA,FDA-2000-D-0187,References,Supporting & Related Material,Background Material,2025-01-16T05:00:00Z,2025,1,,,2025-01-16T16:54:14Z,,0,0,09000064868c1568
FDA-2000-D-0187-0046,FDA,FDA-2000-D-0187,Recommendations To Reduce the Risk of Transfusion-Transmitted Malaria; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2025-01-16T05:00:00Z,2025,1,2025-01-16T05:00:00Z,,2025-01-24T18:59:15Z,2025-01028,0,0,09000064868c6752
FDA-2000-D-0187-0058,FDA,FDA-2000-D-0187,Malaria Guidance 2024-434,Supporting & Related Material,,2025-01-16T00:00:00Z,2025,1,,,2025-01-16T17:11:32Z,,0,1,09000064868c15e2